Search

Your search keyword '"Barisic, Nina"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Barisic, Nina" Remove constraint Author: "Barisic, Nina" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
49 results on '"Barisic, Nina"'

Search Results

1. De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke

2. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

4. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

5. Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)

6. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome

7. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go

8. High association of MOG-IgG antibodies in children with bilateral optic neuritis

9. De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies

10. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.

12. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

13. 255 SUNFISH part 2: risdiplam in type 2 and type 3 SMA

14. Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease

15. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

16. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia

17. Recessive loss-of-function mutations in AP4S1 cause mild fever-sensitive seizures, developmental delay and spastic paraplegia through loss of AP-4 complex assembly

18. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go

19. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

20. Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study.

21. genetic diagnosis; limb-girdle weakness; neuromuscular disease; next-generation sequencing; targeted exome analysisweakness

22. Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene

23. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

24. SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)

25. Biallelic VARS variants cause developmental encephalopathy with microcephaly that is recapitulated in vars knockout zebrafish

26. Significance of GPIbα -5T>C, GPIbα VNTR, GPVI T13254C polymorphisms and HPA-2 in the etiology of pediatric arterial ischemic stroke

27. High Association of MOG-IgG Antibodies in Children with Bilateral Optic Neuritis

28. A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy

29. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy

30. The phenotypic spectrum of SCN8A encephalopathy

31. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data

32. Erratum : De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies (American Journal of Human Genetics (2014) 95(4) (360–370)(S0002929714003838)(10.1016/j.ajhg.2014.08.013))

33. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data

34. Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders.

36. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data

37. De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies.

38. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data

39. Erratum: De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies (American Journal of Human Genetics (2014) 95(4) (360–370)(S0002929714003838)(10.1016/j.ajhg.2014.08.013))

40. Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies

41. Biallelic Variants in OTUD6B Cause an Intellectual Disability Syndrome Associated with Seizures and Dysmorphic Features

42. De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies

43. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia

44. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures

45. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia

46. Chemokines CXCL10, CXCL11, and CXCL13 in acute disseminated encephalomyelitis, non-polio enterovirus aseptic meningitis, and neuroborreliosis: CXCL10 as initial discriminator in diagnostic algorithm?

47. Recessive mutations inSLC13A5result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia

48. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures

Catalog

Books, media, physical & digital resources